Zobrazeno 1 - 10
of 60
pro vyhledávání: '"11"'
Autor:
Kathy Gately, Oscar S. Breathnach, William Grogan, Sinead Toomey, Shereen Rafee, Bryan T. Hennessy, Patrick G. Morris, Kenneth J. O'Byrne, Yasir Elamin, Sinead Cuffe, Aoife Carr
Publikováno v:
Journal of Clinical Oncology. 32:e22174-e22174
e22174 Background: In contrast to lung adenocarcinoma, there are no known targetable oncogenes in lung SQCC. Herein, we thus screened for mutations in 49 kinome-related genes in lung cancer includi...
Publikováno v:
Journal of Clinical Oncology. 38:e21517-e21517
e21517 Background: Genomic profiling of lung adenocarcinoma has been studied, however, different histological subtypes were not carefully distinguished, especially in patients with mixed subtypes. Methods: Fifty-three invasive adenocarcinoma (IA) FFP
Autor:
Sanghoon Jheon, Sung Bum Kang, Koung Jin Suh, Sukki Cho, Duck-Woo Kim, Sang-A Kim, Heung Kwon Oh, Keun-Wook Lee, Jin Won Kim, Ji Won Kim, Jai Young Cho, Jee Hyun Kim, Kwhanmien Kim
Publikováno v:
Journal of Clinical Oncology. 36:843-843
843 Background: Some mCRC pts who have liver and/or lung metastases (LLMs) could achieve cure after palliative chemotherapy and conversion surgery (CS) including metastasectomy. Though targeted agents including bevacizumab and cetuximab significantly
Publikováno v:
Journal of Clinical Oncology. 35:151-151
151 Background: Radiation therapy (RT) is a common palliative treatment for bone metastasis. Despite copious evidence of palliative equipoise between single and multiple fractions, practice patterns vary widely amongst physicians. We evaluate practic
Autor:
Jule Franve Vasquez Chavez, Cindy Alcarraz, Henry L. Gomez, Gerson Mejia, Zaida Morante, Luis Mas, Silvia P. Neciosup, Edgar Amorin
Publikováno v:
Journal of Clinical Oncology. 34:e13088-e13088
e13088Background: Primary malignant mediastinal germ cell tumor (PMMGCT) are rare and have poor prognosis with particularly different biology from those of other germ cell tumor. The aim of this study was to evaluate the clinicopathological features,
Autor:
Remei Blanco, Silvia Catot, Oscar Juan, Alfredo Sanchez-Hernandez, Jose Garcia Sanchez, G. Esquerdo, Sonia Maciá, Francisco Aparisi, Francisco Garcia-Pinon, Jose Vidal, J. Garde
Publikováno v:
Journal of Clinical Oncology. 30:e18053-e18053
e18053 Background: CECs play an important role in tumor neovascularisation and may have prognostic value in cancer patients (pts). The objective of this study is to assess the quantification of CECs as a predictor of response to chemotherapy (CT) in
Autor:
Anthony P.C. Yim, Tony Mok, Kwok Chi Lam, Ka F. To, M. Hsin, Philip C.W. Lui, Simon Ming-Yuen Lee, Innes Y.P. Wan, Li Leung
Publikováno v:
ResearcherID
7667 Background: EGFR mutation is a diverse and complex phenomenon. Shigematsu et al (JNCI 97:339,2005), analyzing NSCLC samples from multiple ethnicities and histologic cell types, reported 11 types of in-frame deletions in exon 19 (46%), 9 missense
Autor:
Stephen K. Williamson, Kathy S. Albain, D. R. Gandara, Martin J. Edelman, Kara M. Kelly, Carolyn C. Gotay, Angela M. Davies, Antoinette J. Wozniak, Joseph M. Unger, Roy S. Herbst
Publikováno v:
Journal of Clinical Oncology. 25:7549-7549
7549 Background: The older lung cancer clinical trial literature suggests that women have better survival than men, possibly due to sex-related changes in drug metabolism based on estrogen levels. A detailed analysis of this issue has not been conduc
Autor:
Maria Giovanna Dal Bello, Angela Alama, E. Bennicelli, Giuseppa De Luca, Simona Coco, Giovanni Rossi, Luca Longo, Marco Mora, Chiara Dellepiane, Lodovica Zullo, Jacopo Ferro, Paolo Pronzato, Marco Tagliamento, Carlo Genova
Publikováno v:
Journal of Clinical Oncology. 39:e21007-e21007
e21007 Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1) have demonstrated activity in the first-line setting of advanced stage non-small cell lung cancer (NSCLC); however, a proportion of patients progr
Publikováno v:
Journal of Clinical Oncology. 39:9103-9103
9103 Background: ICI pneumonitis is an immune-related adverse event (irAE) of the lung and often requires discontinuation of ICI. While some pneumonitis cases resolve within the recommended 4-6-week period of corticosteroid therapy, others either fai